Cryoport, Inc. (Nasdaq: CYRX), a Nashville, Tenn.-based global leader in temperature-controlled supply chain solutions for the life sciences industry, acquired Cell&Co BioServices, a Clermont-Ferrand, France-based bioservices business with additional operations in Pont-du-Château, France.
Cryoport’s purchase price for Cell&Co was €6.2 million, comprised of upfront consideration of €3.6 million in the form of cash and Cryoport common stock, plus a potential earn-out of €2.5M based on achieving certain financial targets.
Founded in 2012 by Sofien Dessolin and Florent Belon, Cell&Co is a bioservices business providing biorepository, kitting, and logistics services to the life sciences industry. Its accreditations include ISO 9001, ANSM (Investigational Medicinal Products), NFS 96 900, and soon, ISO 20387. Supporting its biostorage and services of clinical and commercial biopharma therapies, Cell&Co has in-house QP services.
In 2021, Cell&Co recorded revenue of approximately €2.6 million.
Led by Jerrell Shelton, Chief Executive Officer, Cryoport is a global leader in temperature-controlled supply chain solutions for the life sciences industry supporting life-saving cell and gene therapies across the clinical and commercial spectrum. With 33 strategic locations covering the Americas, EMEA (Europe, the Middle East and Africa) and APAC (Asia Pacific), Its global platform provides mission-critical solutions, services, and products to Biopharma, Animal Health, and Reproductive Medicine customers worldwide. In addition to its standard setting supply chain solutions, Cryoport is the world’s largest manufacturer of cryogenic systems and one of the largest life science focused specialty couriers. As of December 31, 2021, the company supported eight commercial cell and gene therapies and 602 regenerative medicine clinical trials globally, with 74 of these trials in Phase 3.
FinSMEs
18/04/2022